Database Analysis of Eplerenone Use in Japanese Hypertensive Patients in Clinical Practice

Table 3

Combinations of antihypertensive drugs in order of frequency in all patients who received antihypertensive drugs during the last claim month of stable treatment (≥ six months of treatment with the same drugs; combinations with 0.2% or more are shown).

Combinations	N (%)
CCB+ARB	41,462 (25.8)
CCB	35,946 (22.3)
ARB	31,757 (19.7)
D+CCB+ARB	7,048 (4.4)
D+ARB	4,850 (3.0)
BB+CCB+ARB	4,716 (2.9)
BB+CCB	4,663 (2.9)
ACEi+CCB	4,066 (2.5)
BB	4,061 (2.5)
BB+ARB	2,673 (1.7)
ACEi	2,512 (1.6)
AlphaB+CCB+ARB	1,627 (1.0)
BB+D+CCB+ARB	1,444 (0.9)
D+CCB	927 (0.6)
AlphaB+CCB	908 (0.6)
BB+ACEi+CCB	773 (0.5)
BB+ACEi	764 (0.5)
BB+D+ARB	686 (0.4)
D	680 (0.4)
D+AlphaB+CCB+ARB	517 (0.3)
ACEi+CCB+ARB	508 (0.3)
AlphaB+ARB	419 (0.3)
BB+AlphaB+CCB+ARB	370 (0.2)
AlphaB	345 (0.2)
D+ACEi+CCB	315 (0.2)
EPL+CCB+ARB	278 (0.2)

CCB: calcium channel blocker, ARB: angiotensin II receptor blocker, D: diuretics, BB: beta blocker, ACEi: angiotensin-converting-enzyme inhibitor, AlphaB: alpha blocker, and EPL: eplerenone.